Stocks · News reference
Biogen shares are trading higher after UBS maintained its Buy rating and raised its price target on the stock from $240 to $270.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.
UBS Maintains Buy on Biogen, Raises Price Target to $270
UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $240 to $270.